北京万东医疗科技股份有限公司关于 2022 年员工持股计划股票出售完毕暨终止的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 北京万东医疗科技股份有限公司（以下简称"公司"）2022年员工持 股计划所持有的公司股票已全部出售完毕。根据《关于上市公司实施员工 持股计划试点的指导意见》《上海证券交易所上市公司自律监管指引第1号 ——规范运作》等规定，现将相关情况公告如下： 证券代码：600055 证券简称：万东医疗 编号：临 2025-033 北京万东医疗科技股份有限公司 董事会 2025 年 6 月 28 日 截至本公告披露日，公司2022年员工持股计划所持有的公司股票已经 通过集中竞价交易方式全部出售完毕，员工持股计划管理委员会将根据《万 东医疗2022年员工持股计划管理办法》的相关规定及持有人会议的授权开 展清算工作，待相关工作完成后，本员工持股计划终止。 特此公告。 一、员工持股计划的基本情况 公司于2022年4月21日召开第九届董事会第六次会议和第九届监事会 第六次会议、2022年5月13日召开2021年年度股东 ...

证券代码：600055 证券简称：万东医疗 编号：临 2025-032 北京万东医疗科技股份有限公司 关于公司及子公司使用闲置募集资金 及自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 产品种类：银行理财 本次现金管理总额：募集资金 0.5 亿元、自有资金 1.5 亿元 履行的审议程序：2025年 3月 20日召开的第十届董事会第六次会议、 第十届监事会第六次会议及 2025 年 4 月 16 日召开的 2024 年年度股东大会 审议批准《关于使用部分暂时闲置募集资金及自有资金进行现金管理的议 案》。 一、情况概述 （一）现金管理目的 限公司欧元/美元固定日观察区间型结构性存款，本存款所指挂钩标的定盘 价格为彭博页面"BFIX"在东京时间下午 3 点显示的挂钩标的中间价，取 值小数点后五位，本产品协议项下挂钩标的为【欧元兑美元即期汇率】。 2025 年 6 月 12 日，公司子公司万里云医疗信息科技（北京）有限公司 （以下简称"万里云"）以 2,000 万元自有资金购买了招 ...

Core Insights - The medical equipment industry is facing significant price reductions due to centralized procurement initiatives, with many devices seeing price drops exceeding 50% [7][9][12] - The shift towards "price for volume" in procurement is leading to a restructuring of the market, impacting both domestic manufacturers and international competitors [2][5][12] - The competitive landscape is changing, with leading companies benefiting from cash flow while smaller firms may struggle to survive [12][18] Group 1: Price Reductions and Market Dynamics - Centralized procurement in regions like Sichuan, Henan, and Xinjiang is drastically lowering prices for medical equipment, with some devices like 1.5T MRI machines dropping to around 500,000 yuan from 2 million yuan [2][9] - Over 30% of procurement projects have seen price drops exceeding 50%, with 27% experiencing reductions over 70% [7][9] - The average price drop for ultrasound devices is significant, with major players like Mindray securing large orders despite steep price reductions [9][10] Group 2: Impact on Manufacturers - Domestic manufacturers are facing challenges as they attempt to compete with international firms, with many experiencing squeezed profit margins due to aggressive pricing strategies [5][12] - High-end equipment is less affected by price drops, allowing manufacturers in this segment to maintain profitability while increasing sales volume [9][12] - The procurement process is favoring established companies with strong distribution channels, while smaller firms may need to innovate or seek acquisition to remain competitive [12][18] Group 3: Future Trends and Considerations - The focus of procurement policies is shifting from merely achieving low prices to balancing cost with meeting clinical needs, which may create opportunities for innovative products [18][19] - There is a growing recognition of the need for a fair competitive environment that allows for new entrants and maintains market vitality [18][19] - The integration of AI in imaging devices is becoming a standard, potentially impacting pricing and market dynamics for software solutions [13][19]

Group 1 - The core viewpoint of the articles highlights the strategic shift of Beijing Wandong Medical Technology Co., Ltd. (Midea Wandong) from selling DR equipment to providing comprehensive orthopedic solutions, aiming to support private medical institutions in overcoming challenges in the healthcare industry [1][2] - Midea Wandong has served over 30,000 medical institutions annually and has provided more than 100,000 medical imaging devices globally [2] - The company achieved a revenue of 1.524 billion yuan in 2024, representing a year-on-year growth of 23.26% [2] Group 2 - The private hospital sector in China has seen its proportion rise to nearly 70%, yet it only accounts for about 20% of outpatient volume, indicating a disparity in service capacity compared to public hospitals [1] - Midea Wandong aims to leverage its brand advantages to actively participate in ecosystem construction, addressing the challenges faced by private medical institutions and enhancing their capabilities [1] - The company emphasizes the importance of integrating innovative technologies with the development of disciplines and applications in private healthcare, which is a pressing issue that needs to be addressed [1]

Core Insights - The conference focused on the theme of "Breaking through and restructuring under the difficulties of social medical development" [1] - The healthcare industry is undergoing a transformation from "scale expansion" to "value-based healthcare," presenting both challenges and opportunities for private medical institutions [3][4] Industry Challenges - Private hospitals account for nearly 70% of the total number of hospitals in China but only handle about 20% of outpatient visits, indicating a disparity in service capacity [3] - The current healthcare landscape requires private medical institutions to enhance their service and management capabilities to improve risk resilience [3] Company Initiatives - Midea Wandong showcased its comprehensive interventional solutions and orthopedic solutions, emphasizing a "device + technology + scenario" approach to support social medical institutions [1][7] - The company aims to leverage its strengths as a domestic brand to actively participate in the ecological construction of the healthcare industry [7] Innovation and Technology - Midea Wandong has a robust R&D team of over 500 people and collaborates with Midea's AI team to enhance product innovation, such as the "WDL Wide Area Deep Learning Platform" that improves MRI image quality and scanning speed [10] - The company is committed to providing personalized solutions, such as the full-spine DR imaging system, which meets high-intensity screening needs and offers precise data for preoperative planning [11] Future Focus - Midea Wandong plans to concentrate on the entire ecosystem of medical imaging, developing personalized solutions for various clinical scenarios, including orthopedic care and chronic disease management [11]

Investment Rating - The industry investment rating is "Outperform the Market" [4][46]. Core Viewpoints - The total bid amount for medical devices in May 2025 reached 13.43 billion yuan, representing a year-on-year increase of 69% and a cumulative total of 71.45 billion yuan from January to May, with a year-on-year growth of 72% [5][11]. - Domestic medical device companies showed significant growth, with notable increases in ultrasound and endoscope categories [6][20][23]. - Imported brands also experienced rapid growth, particularly in CT equipment, which saw a year-on-year increase of 282% for Siemens in May [7][35]. Summary by Sections Medical Device Procurement Overview - The total bid amount for May 2025 was 13.43 billion yuan, a 69% increase year-on-year, while the cumulative total for January to May was 71.45 billion yuan, up 72% year-on-year [11][12]. Domestic Brands - Major domestic companies like Mindray, United Imaging, and Aohua Endoscopy reported substantial growth in bid amounts, with Mindray achieving 8.19 billion yuan in May, a 56% increase year-on-year [17][18]. - Aohua Endoscopy's bid amount in May was 0.35 billion yuan, reflecting a remarkable 242% year-on-year growth [20][21]. - Other companies like KAILI and Shanfeng also reported significant increases, with KAILI's bid amount growing by 137% in May [23][24]. Imported Brands - Philips reported a bid amount of 6.11 billion yuan in May, a 62% increase year-on-year, while Siemens achieved 11.57 billion yuan, marking a 112% increase [32][35]. - GE's bid amount reached 9.54 billion yuan in May, reflecting a 47% year-on-year growth [38][39]. - The CT segment for Siemens saw a staggering 282% increase in May, highlighting the strong demand for advanced imaging technologies [35][36].

Core Points - The board of directors of Beijing Wandong Medical Technology Co., Ltd. held its ninth meeting of the tenth session on June 9, 2025, via telecommunication voting [1][2] - The meeting was attended by all 8 directors, and the resolutions made were in compliance with the Company Law and the Articles of Association [1] - The board approved a proposal to adjust the members of certain specialized committees to enhance the corporate governance structure [1][2] Committee Adjustments - After the adjustments, Mr. Ma Chibing is a member of both the Strategic Committee and the Compensation and Assessment Committee, serving as the convener of the Strategic Committee [2] - The composition of the Strategic Committee includes Mr. Ma Chibing, Mr. Song Jinsong, Ms. Zhong Zheng, and Mr. Liu Xiao, with Mr. Ma as the convener [2] - The Compensation and Assessment Committee consists of independent directors Mr. Zhao Jun and Ms. Sun Yan, along with Mr. Ma Chibing, with Mr. Zhao as the convener [2] - The voting results for the proposal were unanimous, with 8 votes in favor, 0 against, and 0 abstentions [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 为进一步完善公司治理结构，根据《公司法》《上市公司章程指引》等 相关法律法规的规定，北京万东医疗科技股份有限公司（以下简称"公司"） 召开第十届董事会第八次会议及 2025 年第一次临时股东大会，审议通过了 《关于取消监事会并修订<公司章程>的议案》。依据《公司章程》，公司董 事会由八名董事组成，其中一名为职工代表董事。 公司于 2025 年 6 月 9 日召开职工代表大会，经与会职工代表民主选举， 一致同意选举廉世俊先生为公司第十届董事会职工代表董事（简历详见附 件），任期自 2025 年第一次临时股东大会审议通过《关于取消监事会并修 订<公司章程>的议案》之日起至公司第十届董事会任期届满之日止。 特此公告。 证券代码：600055 证券简称：万东医疗 编号：临 2025-030 北京万东医疗科技股份有限公司 关于选举职工代表董事的公告 董事会 2025 年 6 月 10 日 附件：职工代表董事简历 廉世俊：男，工学硕士。曾任飞利浦医疗中国研发中心研发工程师、 上海西门子医疗 ...

特此公告。 证券代码：600055 证券简称：万东医疗 编号：临 2025-030 北京万东医疗科技股份有限公司 关于选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 为进一步完善公司治理结构，根据《公司法》《上市公司章程指引》等 相关法律法规的规定，北京万东医疗科技股份有限公司（以下简称"公司"） 召开第十届董事会第八次会议及 2025 年第一次临时股东大会，审议通过了 《关于取消监事会并修订<公司章程>的议案》。依据《公司章程》，公司董 事会由八名董事组成，其中一名为职工代表董事。 公司于 2025 年 6 月 9 日召开职工代表大会，经与会职工代表民主选举， 一致同意选举廉世俊先生为公司第十届董事会职工代表董事（简历详见附 件），任期自 2025 年第一次临时股东大会审议通过《关于取消监事会并修 订<公司章程>的议案》之日起至公司第十届董事会任期届满之日止。 北京万东医疗科技股份有限公司 董事会 2025 年 6 月 10 日 附件：职工代表董事简历 廉世俊：男，工学硕士。曾任飞利浦医疗中国研发中 ...

证券代码：600055 证券简称：万东医疗 公告编号：2025-029 北京万东医疗科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2025 年 6 月 9 日 (二) 股东大会召开的地点：公司本部（北京市朝阳区酒仙桥东路 9 号院 3 号楼） (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份 情况： | 1、出席会议的股东和代理人人数 | 202 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 330,324,605 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份 | | | 总数的比例（%） | 46.9837 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情 况等。 会议由公司董事长马赤兵先生主持，采取现场及网络相结合的方式投票 表决并形成会议决议，会议的召集、召开及表决符合《公司法》和《公司 ...